Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KELLY K HUNT and WENDY WOODWARD.
KELLY K HUNT
Connection Strength
1.653
WENDY WOODWARD
  1. Have we made progress in inflammatory breast cancer? Not so fast. Oncology (Williston Park). 2011 Mar; 25(3):276, 278.
    View in: PubMed
    Score: 0.384
  2. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662.
    View in: PubMed
    Score: 0.150
  3. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):637-44.
    View in: PubMed
    Score: 0.139
  4. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73.
    View in: PubMed
    Score: 0.120
  5. Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities. Ann Surg Oncol. 2024 Oct; 31(11):7326-7334.
    View in: PubMed
    Score: 0.061
  6. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44.
    View in: PubMed
    Score: 0.057
  7. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003 Sep 01; 21(17):3244-8.
    View in: PubMed
    Score: 0.057
  8. Inflammatory Breast Cancer at the Extremes of Age. Ann Surg Oncol. 2021 Oct; 28(10):5626-5634.
    View in: PubMed
    Score: 0.049
  9. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2021 10 01; 111(2):360-370.
    View in: PubMed
    Score: 0.049
  10. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol. 2018 Oct 31; JCO1800317.
    View in: PubMed
    Score: 0.041
  11. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg. 2017 03; 265(3):574-580.
    View in: PubMed
    Score: 0.036
  12. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015 Oct; 1(7):931-41.
    View in: PubMed
    Score: 0.033
  13. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
    View in: PubMed
    Score: 0.032
  14. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.030
  15. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28.
    View in: PubMed
    Score: 0.029
  16. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.028
  17. Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: implications for targeting the undissected axilla. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):116-122.
    View in: PubMed
    Score: 0.028
  18. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
    View in: PubMed
    Score: 0.028
  19. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012 Oct 15; 118(20):4936-43.
    View in: PubMed
    Score: 0.026
  20. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011 Oct; 18(11):3164-73.
    View in: PubMed
    Score: 0.025
  21. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):782-7.
    View in: PubMed
    Score: 0.025
  22. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat. 2011 Jul; 128(2):421-7.
    View in: PubMed
    Score: 0.024
  23. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. 2011 Apr 15; 117(8):1595-601.
    View in: PubMed
    Score: 0.023
  24. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010 Sep 01; 116(17):4000-6.
    View in: PubMed
    Score: 0.023
  25. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1296-302.
    View in: PubMed
    Score: 0.023
  26. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):474-84.
    View in: PubMed
    Score: 0.020
  27. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1022-7.
    View in: PubMed
    Score: 0.019
  28. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer. 2007 Dec 01; 110(11):2420-7.
    View in: PubMed
    Score: 0.019
  29. Primary angiosarcomas of the breast. Cancer. 2007 Jul 01; 110(1):173-8.
    View in: PubMed
    Score: 0.019
  30. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1004-9.
    View in: PubMed
    Score: 0.018
  31. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):490-6.
    View in: PubMed
    Score: 0.018
  32. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006 Nov 01; 24(31):4971-5.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.